$6.020
-0.146 (-2.43%)Zum Schluss
Umsatzquellen von AHCO
AdaptHealth Corp. (AHCO) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Insurance, accounting for 61.3% of total sales, equivalent to $453.73M. Other significant revenue streams include Government and Patient Pay. Understanding this composition is critical for investors evaluating how AHCO navigates market cycles within the Medical Equipment, Supplies & Distribution industry.
Profitabilität und Margen von AHCO
Evaluating the bottom line, AdaptHealth Corp. maintains a gross margin of 13.37%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 1.60%, while the net margin is -19.47%. These profitability ratios, combined with a Return on Equity (ROE) of -16.72%, provide a clear picture of how effectively AHCO converts its operational activities into shareholder value.
AHCO im Vergleich zur Peergroup
In the context of the broader market, AHCO competes directly with industry leaders such as DNA and STLN. With a market capitalization of $826.25M, it holds a leading position in the sector. When comparing efficiency, AHCO's gross margin of 13.37% stands against DNA's 91.47% and STLN's 15.70%. Such benchmarking helps identify whether AdaptHealth Corp. is trading at a premium or discount relative to its financial performance.
Finanzielle Entwicklung von AdaptHealth Corp.
AdaptHealth's revenue has shown fluctuations, with a recent Q2 revenue of $740.3 million falling short of the $846.8 million forecast. The gross margin is currently at 13.37%, a decline from previous quarters, reflecting ongoing operational challenges. The company has also reported a negative net income of $133.9 million in Q2 2026, highlighting financial distress.
Financials
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.